



Memo of Understanding between the Screening Applicant and Broad Institute Chemical Biology Platform

Since your small-molecule screening application has been approved for the research objective stated in your BROAD INSTITUTE CHEMICAL BIOLOGY PLATFORM HIGH-THROUGHPUT SCREENING SERVICES APPLICATION, you, the Principal Investigator (and any person that you designate to work on the screening project on your behalf (a "Designee"), will have the opportunity to work with the Broad Institute's Chemical Biology Platform ("BCB Platform"). Clarity on our mutual expectations for how data will be generated, shared and published is essential to a successful collaboration.

Your project will be screened against the Broad Institute Screening Collection, a diverse collection of small molecules of known purity and structure that have been created by Broad chemists or purchased with Broad funds. In some cases, there may be circumstances in which we mutually agree to pursue follow-up chemistry; these activities, which are beyond the scope of this initial screening project, would constitute a **new** research collaboration.

You will work with a dedicated "chaperone" at the Broad Institute, who will function as your point of contact with the BCB Platform. Your chaperone will help you to create a Screening Plan based on the research objective, aimed at ensuring that your assay is reflective of the underlying biology and is compatible with the industry-standard, high-throughput automated robotic systems installed at the Broad Institute. This Screening Plan will help ensure that you understand and agree with the anticipated outcomes of the screen. The typical scope of a Screening Plan encompasses a high throughput screen (run in duplicate at a single compound concentration), custom compound picks of the compounds in the active wells and re-testing of the active compounds (run in duplicate and with multiple doses of compound).

Data obtained from your screening project will be delivered to the screener by the BCB Platform upon completion of the screening campaign. The deposit of data into the BCB Platform's database does not constitute a public disclosure. In this way, those who deposit data, can preserve their ability to publish or patent the results of their work if they so choose. If your funding source requires public disclosure of screening data we are able and willing to make the data available in PubChem (<http://pubchem.ncbi.nlm.nih.gov/>). PubChem has the ability to hold the data and maintain its confidential integrity for one year by use of a "Hold Until" date. BCB will enact this hold if you desire.

Patenting of Results

We ask that you notify the Broad Institute's Office of Business Development, [attn: Terese Dillingham (teresed@broadinstitute.org)], of any intellectual property generated from the results of the Research Objective, so that the BCB Platform may meet its reporting requirements to funding sources.

We ask that you acknowledge that BCB personnel and/or other contributors to the project may be co-inventors of any new intellectual property, depending on the degree and extent of their contribution to the screening project, in accordance with U.S. patent law and determined by



outside counsel.

We ask that you acknowledge that the compounds used in this project were obtained from a variety of sources; therefore, the BCB Platform will determine the origin of any hits arising from this screen to facilitate an appropriate strategy for patent filings.

Publications

In any collaboration, it is important that the collaborating organizations and scientists receive the appropriate acknowledgement and authorship.

We ask that you understand that it is your responsibility to acknowledge financial support formally of any work performed on this project in all presentations and publications as required by the funding source (to be determined before screening begins).

We ask that you acknowledge the BCB Platform in any publications or presentations resulting from your screening project at the Broad Institute. Additional acknowledgments or co-authorship may be appropriate, depending on the degree and extent of contribution by others. In cases where significant intellectual contribution has been made to your project (e.g., novel chemistry, assay development, screening strategies, data analysis methods, etc.), we ask you to agree to consider co-authorship for the appropriate scientists in accordance with scientific and academic custom. If co-authorship is not appropriate, we ask you to acknowledge other researchers, as appropriate, if their work has contributed to a paper you write, or a presentation you give. In general, when there is any question about proper attribution, please contact the Director of the BCB Platform for guidance.

Because tracking success of the BCB Platform screening is important to the multiple funding sources and to future funding, we ask that you notify BCB Platform if any work performed in the BCB Platform facilities results in a publication.

Project Title: _____

Read and Understood by:

_____	_____	_____
PI: Print Name	Sign Name	Date

_____	_____	_____
Designee: Print Name	Sign Name	Date